Pyxis Oncology, Inc. — Director's Dealing 2021

Dec 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-12-06

Reporting Person: Yanchik Connealy Pamela (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-06	Stock Option (Right to buy)	$9.64	A	52944	Acquired	2031-12-06	Common Stock (52944)	Direct

Footnotes

F1: These stock options vest 25% on July 19, 2022, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.